tradingkey.logo

Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum

ReutersJan 12, 2026 1:35 PM

- Mirum Pharmaceuticals Inc MIRM.O:

  • MIRUM PHARMACEUTICALS ANNOUNCES PRELIMINARY UNAUDITED 2025 RESULTS, DEMONSTRATING STRONG COMMERCIAL GROWTH AND PIPELINE MOMENTUM

  • MIRUM PHARMACEUTICALS INC - PRELIM 2025 NET PRODUCT SALES OF APPROXIMATELY $520 MILLION EXCEED UPPER END OF GUIDANCE

  • MIRUM PHARMACEUTICALS INC - 2026 EXPECTED GLOBAL NET PRODUCT SALES OF $630 MILLION TO $650 MILLION

  • MIRUM PHARMACEUTICALS INC - VOLIXIBAT VISTAS STUDY IN PRIMARY SCLEROSING CHOLANGITIS (PSC) TOPLINE DATA EXPECTED Q2 2026

  • MIRUM PHARMACEUTICALS INC - LIVMARLI EXPAND STUDY IN ADDITIONAL CHOLESTATIC PRURITUS SETTINGS TIMING ACCELERATED; TOPLINE DATA NOW EXPECTED Q4 2026

  • MIRUM PHARMACEUTICALS - BLUEJAY THERAPEUTICS' AZURE-1 STUDY IN HDV INTERIM DATA EXPECTED IN Q2 2026, TOPLINE PHASE 3 DATA EXPECTED IN H2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI